FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983157066> ?p ?o ?g. }

• W1983157066 endingPage "2237" @default.
• W1983157066 startingPage "2227" @default.
• W1983157066 abstract "End-stage hypertensive heart disease is an increasing cause of cardiac mortality. Therefore, the current study focused on the cardiac remodelling from hypertrophy to fibrosis in old-aged spontaneously hypertensive rats (SHRs), and explored the therapeutic effects of Rosuvastatin and its possible mechanism(s) of action. Spontaneously hypertensive rats at age 52 weeks were randomly divided into three groups, the first two to receive Rosuvastatin at a dose of 20 mg/kg/day and 40 mg/kg/day, respectively, and the third to receive placebo, which was to be compared with Wistar-Kyoto as controls. After 2-month treatment, SBP, heart to body weight ratio (HW/BW%) and echocardiographic features were evaluated, followed by haematoxylin and eosin and Masson trichrome staining in conjunction with qPCR of foetal gene expressions. Transferase-mediated dUTP nick-end labelling assay and immunofluorescent labelling for active caspase-3 were used to detect the apoptotic cardiomyocytes. Signaling pathways involved were examined by using western blot. Old-aged SHR developed end-stage hypertensive heart disease characterized by significant enhancement of HW/BW%, LVAWd and LVPWd, and decreased LVEF and LVFS, accompanied by cardiomyocytes enlargement and fibrosis along with activation of foetal gene programme. Cardiac apoptosis increased significantly during the transition process. Rosuvastatin reduced hypertrophy significantly via AT1 Receptor-PKCβ2/α-ERK-c-fos pathway; protected myocardium against apoptosis via Akt-FOXO1, Bcl-2 family and survivin pathways and consequently suppressed the caspase-3 activity. The present study revealed that old-aged SHRs developed cardiac remodelling from hypertrophy to fibrosis via cardiac apoptosis during the end stage of hypertensive heart disease. These pathological changes might be the consequence of activation of AT1 Receptor-PKCβ2/α-ERK-c-fos and AKT-FOXO1/Bcl-2/survivin/Caspase3 signaling. Rosuvastatin effectively attenuated the structural changes by reversing the signaling transductions involved." @default.
• W1983157066 created "2016-06-24" @default.
• W1983157066 creator A5001624794 @default.
• W1983157066 creator A5026577269 @default.
• W1983157066 creator A5053743858 @default.
• W1983157066 creator A5055672231 @default.
• W1983157066 creator A5066459425 @default.
• W1983157066 creator A5071718807 @default.
• W1983157066 creator A5073480094 @default.
• W1983157066 creator A5076823638 @default.
• W1983157066 creator A5078164215 @default.
• W1983157066 creator A5084099890 @default.
• W1983157066 creator A5091261631 @default.
• W1983157066 date "2012-08-23" @default.
• W1983157066 modified "2023-10-12" @default.
• W1983157066 title "The therapeutic effect of Rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats" @default.
• W1983157066 cites W1489063373 @default.
• W1983157066 cites W1582802379 @default.
• W1983157066 cites W1965235907 @default.
• W1983157066 cites W1968419106 @default.
• W1983157066 cites W1969100688 @default.
• W1983157066 cites W1976791051 @default.
• W1983157066 cites W1980691914 @default.
• W1983157066 cites W1982685027 @default.
• W1983157066 cites W1983679827 @default.
• W1983157066 cites W1986508379 @default.
• W1983157066 cites W1987383080 @default.
• W1983157066 cites W1999654312 @default.
• W1983157066 cites W2006434763 @default.
• W1983157066 cites W2011830144 @default.
• W1983157066 cites W2018183883 @default.
• W1983157066 cites W2031643167 @default.
• W1983157066 cites W2050546968 @default.
• W1983157066 cites W2051441972 @default.
• W1983157066 cites W2054635410 @default.
• W1983157066 cites W2056694369 @default.
• W1983157066 cites W2064001901 @default.
• W1983157066 cites W2068769540 @default.
• W1983157066 cites W2082136987 @default.
• W1983157066 cites W2086627977 @default.
• W1983157066 cites W2098328780 @default.
• W1983157066 cites W2115728523 @default.
• W1983157066 cites W2121061143 @default.
• W1983157066 cites W2126452437 @default.
• W1983157066 cites W2130760108 @default.
• W1983157066 cites W2144896295 @default.
• W1983157066 cites W2152323530 @default.
• W1983157066 cites W2164725116 @default.
• W1983157066 cites W2170078866 @default.
• W1983157066 cites W2171820373 @default.
• W1983157066 cites W2172111517 @default.
• W1983157066 cites W2247997571 @default.
• W1983157066 cites W4254209755 @default.
• W1983157066 doi "https://doi.org/10.1111/j.1582-4934.2012.01536.x" @default.
• W1983157066 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3822992" @default.
• W1983157066 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22288611" @default.
• W1983157066 hasPublicationYear "2012" @default.
• W1983157066 type Work @default.
• W1983157066 sameAs 1983157066 @default.
• W1983157066 citedByCount "29" @default.
• W1983157066 countsByYear W19831570662012 @default.
• W1983157066 countsByYear W19831570662013 @default.
• W1983157066 countsByYear W19831570662014 @default.
• W1983157066 countsByYear W19831570662015 @default.
• W1983157066 countsByYear W19831570662016 @default.
• W1983157066 countsByYear W19831570662017 @default.
• W1983157066 countsByYear W19831570662018 @default.
• W1983157066 countsByYear W19831570662019 @default.
• W1983157066 countsByYear W19831570662020 @default.
• W1983157066 countsByYear W19831570662022 @default.
• W1983157066 crossrefType "journal-article" @default.
• W1983157066 hasAuthorship W1983157066A5001624794 @default.
• W1983157066 hasAuthorship W1983157066A5026577269 @default.
• W1983157066 hasAuthorship W1983157066A5053743858 @default.
• W1983157066 hasAuthorship W1983157066A5055672231 @default.
• W1983157066 hasAuthorship W1983157066A5066459425 @default.
• W1983157066 hasAuthorship W1983157066A5071718807 @default.
• W1983157066 hasAuthorship W1983157066A5073480094 @default.
• W1983157066 hasAuthorship W1983157066A5076823638 @default.
• W1983157066 hasAuthorship W1983157066A5078164215 @default.
• W1983157066 hasAuthorship W1983157066A5084099890 @default.
• W1983157066 hasAuthorship W1983157066A5091261631 @default.
• W1983157066 hasBestOaLocation W19831570662 @default.
• W1983157066 hasConcept C126322002 @default.
• W1983157066 hasConcept C134018914 @default.
• W1983157066 hasConcept C167414201 @default.
• W1983157066 hasConcept C2777420927 @default.
• W1983157066 hasConcept C2778198053 @default.
• W1983157066 hasConcept C2780045698 @default.
• W1983157066 hasConcept C2780499067 @default.
• W1983157066 hasConcept C2780559512 @default.
• W1983157066 hasConcept C71924100 @default.
• W1983157066 hasConceptScore W1983157066C126322002 @default.
• W1983157066 hasConceptScore W1983157066C134018914 @default.
• W1983157066 hasConceptScore W1983157066C167414201 @default.
• W1983157066 hasConceptScore W1983157066C2777420927 @default.
• W1983157066 hasConceptScore W1983157066C2778198053 @default.
• W1983157066 hasConceptScore W1983157066C2780045698 @default.

• next